期刊文献+

基于TCGA数据库探究肾透明细胞癌关键基因的表达及预后作用

The expression and prognostic value of key genes in clear cell renal cell carcinoma(ccRCC) utilizing TCGA datasets
下载PDF
导出
摘要 目的:探究肾透明细胞癌中关键基因的表达及预后作用,寻找潜在治疗靶点。方法:从TCGA数据库下载肾透明细胞癌mRNA的表达数据,通过Rstudio软件分析肿瘤与正常组织间差异表达基因,对差异表达基因进行富集分析、蛋白-蛋白相互作用网络构建,并分析出关键基因,最后对关键基因进行预后分析。结果:得到1 855个差异表达基因,其中有1 207个是上调的,648个是下调的,富集分析发现差异基因主要与信号转导、物质代谢、免疫反应等信号通路相关。筛选出10个关键基因中有6个存在预后价值。结论:筛选出的差异基因及信号通路可以帮助我们探索肾透明细胞癌发病的分子机制,同时为靶向治疗的研究提供潜在的理论依据。 Objective:To explore the expression and prognosis of hub genes in clear cell renal cell carcinoma(ccRCC) and to find potential therapeutic targets.Methods:mRNA expression data of clear cell renal cell carcinoma was downloaded from the TCGA datasets.Then the differentially expressed genes(DEGs) were identified between normal and tumor tissues by using Rstudio software.After that,we performed enrichment analysis and constructed the protein-protein interaction networks of DEGs.Finally,hub genes were find out and the prognostic value of the hub genes was analyzed.Results:1 855 DEGs were obtained,of which 1 207 were up-regulated and 648 were down-regulated.The result of enrichment analysis showed that the DEGs were related to signal transduction,substance metabolism,immune response and other signaling pathways.And six of the ten hub genes had prognostic value.Conclusion:The selected DEGs and signaling pathways can help us explore the molecular mechanism of the pathogenesis of clear cell renal cell carcinoma and provide a potential theoretical basis for the study of targeted therapy.
作者 张冲 汤玉锐 关翰 汪亚辉 韩兵 姚越 熊言骏 汪盛 Zhang Chong;Tang Yurui;Guan Han;Wang Yahui;Han Bing;Yao Yue;Xiong Yanjun;Wang Sheng(The First Affiliated Hospital of Bengbu Medical College,Anhui Bengbu 233004,China)
出处 《现代肿瘤医学》 CAS 2020年第19期3294-3298,共5页 Journal of Modern Oncology
基金 安徽省自然科学基金面上项目(编号:1808085MH293)。
关键词 TCGA 肾透明细胞癌 关键基因 预后价值 TCGA clear cell renal cell carcinoma hub genes prognostic value
  • 相关文献

参考文献8

二级参考文献60

  • 1Normann SJ, Sorkin E. Inhibition of marcophage chemotaxis by neoplasitic and other rapidly proliferating ceils in vitro[J].Cancer Res, 1977,37(3) : 705.
  • 2Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer[J] ? Nature Rev Immunol, 2002,2(3) : 175.
  • 3Oppenheim JJ, Murphy WJ, Chertox O, et al. Prospects for cytokine and chemokine biotherapy [J]. Clin Cancer Res,1997,3(12) :2682.
  • 4Hogaboam CM, Bone-Larson C, Matsukawa A, et al. Therapeutic use of chemokines[J]. Curr Pharm Des, 2000,6(6):651.
  • 5Devora R, Zlotnik A. The biology of ehemokines and their receptors[J]. Annu Rev Immunol, 2000,18:217.
  • 6Horuk R. Survey.. Chemokine receptors [J]. Cytokine Growth Factor Rev,2001,12(4) :313.
  • 7Gerard C, Rollins BJ. Chemokines and disease[J]. Nat Immunol, 2001,2(2) :108.
  • 8Rottman JB. Key role of CXC chemokines and chemokine receptors in inflammation, immunity, neoplasia, and infectious disease[J]. Vet Pathol, 1999,36(5) :357.
  • 9Balkwill F, Mantovani A. Inflammation and cancer: back to virehow[J]? Lancet,2001,357(9255) :539.
  • 10Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines[J]. Lab Invest,1994,71(1) :5.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部